This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioProcess International US West

Attendee Deadline to Submit a Poster Abstract

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
February 27 - March 2, 2023San Diego Convention Center

Arnaud Deladeriere
Director of Process Development at Triumvira Immunologics Inc.


Arnaud Deladeriere is the Director of Process Development at Triumvira Immunologics Inc., a clinical stage biotech company focusing on the development of the TAC technology, a T-Cell Antigen Coupler that allows T cells to recognize tumors and to kill them by co-opting the endogenous TCR receptor. Arnaud’s main focus at Triumvira is to further develop the company’s products, both autologous and allogeneic TAC-T cells, against several tumor antigens such as HER2 (breast, ovarian, colorectal), or Claudin18.2 (GI). He is particularly involved and interested in the full automation of these processes. Prior to Triumvira, Arnaud was working at a Canadian CDMO for Cell and Gene Therapy called C3i Center, based in Montreal, Canada. There, he developed expertise in GMP Manufacturing and Analytical Development of cell-based therapies. Arnaud received his Ph.D. in Cell and Molecular Biology from the University of Cambridge, UK, during which he studied signaling pathways (centered around PI3K) in several immune cell types, sparking his interest for cell-based therapies early on.

Agenda Sessions

  • Multiplying Strategic Partnerships to Enable the Automation and Scale-out of our Autologous Process